Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The world’s political tectonic plates may be shifting, but this has done little to undermine the achievements of the pharma, biotech and allied industries over the past year, and last night we celebrated the best of these at the 12th annual Scrip Awards in London.
In a lavish ceremony presented by the broadcaster Jeremy Vine, most recently seen walking all over the BBC’s US election night virtual map, Scrip rewarded excellence across the whole range of business activities between June 2015 and May 2016.
2016 has proved to be an interesting year in many unexpected ways, creating uncertainty for our sector. But against a changing political backdrop, industry has continued to develop innovative new drugs, make strides in scientific research and forge new alliances. New investment continues to flow into biotech even as we grapple with pricing and the coming of age of biosimilars.
The Scrip Awards categories range from those that reward the broader achievements of companies, to those for innovation in deal making, advances in R&D and the more personal accomplishments of teams and individuals. New this year, we added the Community Partnership of the Year award to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community.
Overall, Genmab was the big winner of the night, receiving two trophies, but the loudest applause went to this year’s Lifetime Achievement Award recipient, Dr. Raymond F. Schinazi.
See the full list of the 2016 Scrip Awards winners here: http://www.scripawards.com/2016-winners/
Scrip: industry news and insights
04 Jun 2023
Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases...
Scrip: industry news and insights
04 Jun 2023
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential...
Scrip: industry news and insights
03 Jun 2023
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
